Subsequently, Western blot analysis of tumor tissue lysates from A549-BRG1 tumors revealed reduced pEGFRTyr1068, EGFR, and vimentin expression, which was further attenuated following gefitinib treatment (Figure 4E, p < 0.05), relative to their expression levels in gefitinib- and DMSO-treated A549-Puro tumors. Here, VIM is linked to neoplasm.